Emergent BioSolutions Inc（EBS）财务数据EBSEmergent BioSolutions Inc

Emergent BioSolutions Inc. (EBS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial Product sales, accounting for 47.9% of total sales, equivalent to $67.50M. Other significant revenue streams include MCM Product sales and Contracts and grants. Understanding this composition is critical for investors evaluating how EBS navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Emergent BioSolutions Inc. maintains a gross margin of 58.56%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 28.25%, while the net margin is -76.91%. These profitability ratios, combined with a Return on Equity (ROE) of -40.29%, provide a clear picture of how effectively EBS converts its operational activities into shareholder value.

In the context of the broader market, EBS competes directly with industry leaders such as IRD and FULC. With a market capitalization of $306.10M, it holds a leading position in the sector. When comparing efficiency, EBS's gross margin of 58.56% stands against IRD's 100.00% and FULC's N/A. Such benchmarking helps identify whether Emergent BioSolutions Inc. is trading at a premium or discount relative to its financial performance.

EBS reported a total revenue of $234.3 million for Q2 2026, a 66% increase year-over-year, but this was overshadowed by a net loss of $180.2 million, indicating financial strain. The gross margin stands at 58.56%, showing some operational efficiency, but the overall financial health remains concerning.